At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ONC BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS
Trading 10-29 12:14:59 EDT
371.77
-1.59
-0.43%
High376.50Low371.64Vol94.90K
Open373.15D1 Closing373.36Amplitude1.30%
Mkt Cap42.38BTradable Cap30.10BTotal Shares114.00M
T/O35.48MT/O Rate0.12%Tradable Shares80.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 29.22%, and institutional views are bullish
Earnings Agent  ·  10-29 17:00
Earning Preview: BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS this quarter’s revenue is expected to increase by 29.22%, and institutional views are bullish
BeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans
Stock News  ·  10-29 09:32
BeOne Medicines Shares Open Nearly 4% Higher as Company Unveils Clinical Data for Multiple Solid Tumour Programs with Clear Future Development Plans
CICC: BeiGene's solid tumor pipeline sees multiple advances, maintains "Outperform" rating and HK$266 target price
Stock News  ·  10-28 10:04
CICC: BeiGene's solid tumor pipeline sees multiple advances, maintains "Outperform" rating and HK$266 target price
RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)
TIPRANKS  ·  10-28 09:56
RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)
BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026
TIPRANKS  ·  10-26
BeOne Medicines presents new data across solid tumor disease areas at ESMO 2026
BeOne Says Tevimbra Combination Demonstrates Sustained Survival Benefit in Phase 3 Cancer Trial
MT Newswires Live  ·  10-23
BeOne Says Tevimbra Combination Demonstrates Sustained Survival Benefit in Phase 3 Cancer Trial
Press Release: BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
Dow Jones  ·  10-22
Press Release: BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), United Therapeutics (UTHR) and BeOne Medicines (ONC)
TIPRANKS  ·  10-18
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), United Therapeutics (UTHR) and BeOne Medicines (ONC)
BeOne Medicines up Nearly 6%, on Pace for Largest Percent Increase Since November 2025
Dow Jones  ·  10-16
BeOne Medicines up Nearly 6%, on Pace for Largest Percent Increase Since November 2025
Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.05% in Regular Trading, Innovation Drug Stocks Strengthen Alongside Bullish Institutional View
Market Focus  ·  10-15
Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.05% in Regular Trading, Innovation Drug Stocks Strengthen Alongside Bullish Institutional View
Big Pharma is Pouring Billions into a New Class of 'Protein Degrader' Drugs
Dow Jones  ·  10-15
Big Pharma is Pouring Billions into a New Class of 'Protein Degrader' Drugs
Hong Kong Market Close (Oct 15): Hang Seng Index Falls 1.03% as AI Hardware, Shipping, and Non-Ferrous Metal Stocks Decline; Lenovo Group Leads Blue-Chip Losses
Stock News  ·  10-15
Hong Kong Market Close (Oct 15): Hang Seng Index Falls 1.03% as AI Hardware, Shipping, and Non-Ferrous Metal Stocks Decline; Lenovo Group Leads Blue-Chip Losses
Truist Financial Remains a Buy on BeOne Medicines (ONC)
TIPRANKS  ·  10-09
Truist Financial Remains a Buy on BeOne Medicines (ONC)
Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Falls 5.1% in Regular Trading, Founding Shareholder's Recent Consecutive Share Reductions Weigh on Sentiment
Market Focus  ·  10-08
Movement Alert｜BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Falls 5.1% in Regular Trading, Founding Shareholder's Recent Consecutive Share Reductions Weigh on Sentiment
BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus
TIPRANKS  ·  09-29
BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus
Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge
Deep News  ·  09-23
Hong Kong Stocks Open Mixed: Hang Seng Edges Down 0.09%, Tech Index Flat, Memory Chip Plays Surge
BeOne Medicines Advances BG-85738 Into First-in-Human RAS Cancer Trial
TIPRANKS  ·  09-12
BeOne Medicines Advances BG-85738 Into First-in-Human RAS Cancer Trial
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Stock News  ·  09-07
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors
Stock News  ·  09-04
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors
Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements
Reuters  ·  09-01
Global Pharma Companies That Have Publicly Announced Trump Drug Pricing Agreements
No data available

Introduction

Company Name.
BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Issue price:
--